<p>波士頓，2025 年 12 月 15 日（環球新聞）—— Tiziana Life Sciences, Ltd.（納斯達克：TLSA）（“Tiziana” 或 “公司”）是一家生物技術公司，正在開發突破性的免疫調節療法，其主要開發候選藥物為鼻用 foralumab，這是一種完全人源的抗 CD3 單克隆抗體。今天宣佈其首席執行官 Ivor Elrifi 在公開市場購買了 163,400 股 Tiziana 普通股。這使得他目前購買的股票總數達到 357,848 股。</p>
<p><strong>關於 Foralumab</strong></p>
<p>Foralumab 是一種完全人源的抗 CD3 單克隆抗體，是一種生物藥物候選藥物，已顯示在鼻用給藥時能夠刺激 T 調節細胞。目前，已有 14 名非活動性繼發性進展性多發性硬化症（na-SPMS）患者在一個開放標籤的中型擴展接入（EA）項目（NCT06802328）中接受了給藥，所有患者在 6 個月內均觀察到疾病改善或穩定。此外，鼻用 foralumab 目前正在進行一項針對非活動性繼發性進展性多發性硬化症患者的 2a 期隨機雙盲安慰劑對照多中心劑量範圍試驗（NCT06292923）。</p>
<p>Foralumab 是目前唯一在臨牀開發中的完全人源抗 CD3 單克隆抗體（mAb）。鼻用 foralumab 的免疫調節代表了治療神經炎症和神經退行性人類疾病的新途徑。[1],[2]</p>
<p><strong>關於 Tiziana Life Sciences</strong></p>
<p>Tiziana Life Sciences 是一家臨牀階段的生物製藥公司，開發突破性療法，利用變革性的藥物遞送技術實現免疫療法的替代給藥途徑。Tiziana 的創新鼻用方法有潛力在療效、安全性和耐受性方面提供比靜脈（IV）給藥更好的改善。Tiziana 的主要候選藥物鼻用 foralumab 是目前唯一在臨牀開發中的完全人源抗 CD3 單克隆抗體，已在目前的研究中顯示出良好的安全性和臨牀反應。Tiziana 的替代免疫療法技術已獲得專利，多個申請正在審理中，預計將允許廣泛的產品線應用。</p>
<p>有關 Tiziana Life Sciences 及其創新療法管線的更多信息，請訪問 www.tizianalifesciences.com。</p>
<p>如需進一步諮詢：</p>
<p><strong>Tiziana Life Sciences Ltd</strong></p>
<p>Paul Spencer，業務發展和投資者關係</p>
<p>+44 (0) 207 495 2379</p>
<p>電子郵件：info@tizianalifesciences.com</p>
<p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
<p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qVXlNU00zTXpJeU9UVTVJekl4TWpNNE9EVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qVXlNU00zTXpJeU9UVTVJekl4TWpNNE9EVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTFkNWIxZDMtYTU4Mi00NDgzLWIzZTctYTAzYzkwOWEyOTc3LTExMzU0NTYtMjAyNS0xMi0xNS1lbg==/tiny/Tiziana-Life-Sciences-Plc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTFkNWIxZDMtYTU4Mi00NDgzLWIzZTctYTAzYzkwOWEyOTc3LTExMzU0NTYtMjAyNS0xMi0xNS1lbg==/tiny/Tiziana-Life-Sciences-Plc.png"/></p>

TLSA

<p>Tiziana Life Sciences 宣佈其首席執行官 Ivor Elrifi 購買了 163,400 股公司股票，使其總持股量增加至 357,848 股。Tiziana 是一家生物技術公司，正在開發用於治療神經炎症疾病的鼻用 foralumab，這是一種完全人源化的抗 CD3 單克隆抗體。該公司正在進行這一創新療法的臨牀試驗，該療法在非活動性繼發性進展型多發性硬化症患者中顯示出良好的效果</p>

<p>BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.</p>
<div class="lb-trans"><p>波士頓，2025 年 12 月 15 日（環球新聞）—— Tiziana Life Sciences, Ltd.（納斯達克：TLSA）（“Tiziana” 或 “公司”）是一家生物技術公司，正在開發突破性的免疫調節療法，其主要開發候選藥物為鼻用 foralumab，這是一種完全人源的抗 CD3 單克隆抗體。今天宣佈其首席執行官 Ivor Elrifi 在公開市場購買了 163,400 股 Tiziana 普通股。這使得他目前購買的股票總數達到 357,848 股。</p>
</div><p><strong>About Foralumab</strong></p>
<div class="lb-trans"><p><strong>關於 Foralumab</strong></p>
</div><p>Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).</p>
<div class="lb-trans"><p>Foralumab 是一種完全人源的抗 CD3 單克隆抗體，是一種生物藥物候選藥物，已顯示在鼻用給藥時能夠刺激 T 調節細胞。目前，已有 14 名非活動性繼發性進展性多發性硬化症（na-SPMS）患者在一個開放標籤的中型擴展接入（EA）項目（NCT06802328）中接受了給藥，所有患者在 6 個月內均觀察到疾病改善或穩定。此外，鼻用 foralumab 目前正在進行一項針對非活動性繼發性進展性多發性硬化症患者的 2a 期隨機雙盲安慰劑對照多中心劑量範圍試驗（NCT06292923）。</p>
</div><p>Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]</p>
<div class="lb-trans"><p>Foralumab 是目前唯一在臨牀開發中的完全人源抗 CD3 單克隆抗體（mAb）。鼻用 foralumab 的免疫調節代表了治療神經炎症和神經退行性人類疾病的新途徑。[1],[2]</p>
</div><p><strong>About Tiziana Life Sciences</strong></p>
<div class="lb-trans"><p><strong>關於 Tiziana Life Sciences</strong></p>
</div><p>Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.</p>
<div class="lb-trans"><p>Tiziana Life Sciences 是一家臨牀階段的生物製藥公司，開發突破性療法，利用變革性的藥物遞送技術實現免疫療法的替代給藥途徑。Tiziana 的創新鼻用方法有潛力在療效、安全性和耐受性方面提供比靜脈（IV）給藥更好的改善。Tiziana 的主要候選藥物鼻用 foralumab 是目前唯一在臨牀開發中的完全人源抗 CD3 單克隆抗體，已在目前的研究中顯示出良好的安全性和臨牀反應。Tiziana 的替代免疫療法技術已獲得專利，多個申請正在審理中，預計將允許廣泛的產品線應用。</p>
</div><p>For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.</p>
<div class="lb-trans"><p>有關 Tiziana Life Sciences 及其創新療法管線的更多信息，請訪問 www.tizianalifesciences.com。</p>
</div><p>For further inquiries:</p>
<div class="lb-trans"><p>如需進一步諮詢：</p>
</div><p><strong>Tiziana Life Sciences Ltd</strong></p>
<div class="lb-trans"><p><strong>Tiziana Life Sciences Ltd</strong></p>
</div><p>Paul Spencer, Business Development, and Investor Relations</p>
<div class="lb-trans"><p>Paul Spencer，業務發展和投資者關係</p>
</div><p>+44 (0) 207 495 2379</p>
<div class="lb-trans"><p>+44 (0) 207 495 2379</p>
</div><p>email: info@tizianalifesciences.com</p>
<div class="lb-trans"><p>電子郵件：info@tizianalifesciences.com</p>
</div><p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
<div class="lb-trans"><p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
</div><p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
<div class="lb-trans"><p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qVXlNU00zTXpJeU9UVTVJekl4TWpNNE9EVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMjUyMSM3MzIyOTU5IzIxMjM4ODU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTFkNWIxZDMtYTU4Mi00NDgzLWIzZTctYTAzYzkwOWEyOTc3LTExMzU0NTYtMjAyNS0xMi0xNS1lbg==/tiny/Tiziana-Life-Sciences-Plc.png" alt="" original-src="https://ml.globenewswire.com/media/MTFkNWIxZDMtYTU4Mi00NDgzLWIzZTctYTAzYzkwOWEyOTc3LTExMzU0NTYtMjAyNS0xMi0xNS1lbg==/tiny/Tiziana-Life-Sciences-Plc.png"/></p>

Tiziana Life Sciences 宣佈其首席執行官購買公司股票 | TLSA 股票新聞